STK11 and non-small cell lung carcinoma: Recently, the first-in-class AXL inhibitor bemcentinib (R428/BGB324) has been granted fast-track designation by the U.S. Food and Drug Administration (FDA) in STK11-mutated advanced metastatic non-small cell lung cancer (NSCLC)11.